These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 16624605)

  • 1. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.
    Yuen KC; Dunger DB
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S55-61. PubMed ID: 16624605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
    Yuen KC; Dunger DB
    Diabetes Obes Metab; 2007 Jan; 9(1):11-22. PubMed ID: 17199714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy.
    Attallah H; Friedlander AL; Hoffman AR
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S62-7. PubMed ID: 16624603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency.
    Yuen KC; Dunger DB
    Clin Endocrinol (Oxf); 2006 May; 64(5):549-55. PubMed ID: 16649975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.
    Hussain MA; Schmitz O; Mengel A; Glatz Y; Christiansen JS; Zapf J; Froesch ER
    J Clin Invest; 1994 Sep; 94(3):1126-33. PubMed ID: 8083353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
    Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults.
    Yuen K; Ong K; Husbands S; Chatelain P; Fryklund L; Gluckman P; Ranke M; Cook D; Rosenfeld R; Wass J; Dunger D
    J Clin Endocrinol Metab; 2002 May; 87(5):1989-95. PubMed ID: 11994330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen-deficient women.
    Franco C; Koranyi J; Brandberg J; Lönn L; Bengtsson BK; Svensson J; Johannsson G
    Growth Horm IGF Res; 2009 Apr; 19(2):112-20. PubMed ID: 18752977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are the metabolic effects of GH and IGF-I separable?
    Mauras N; Haymond MW
    Growth Horm IGF Res; 2005 Feb; 15(1):19-27. PubMed ID: 15701568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in nutritional status].
    Chevenne D; Porquet D
    Ann Biol Clin (Paris); 1995; 53(10-11):527-38. PubMed ID: 8787278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor I and impaired glucose tolerance.
    Dunger D; Yuen K; Ong K
    Horm Res; 2004; 62 Suppl 1():101-7. PubMed ID: 15761241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for distinct effects of GH and IGF-I in the metabolic syndrome.
    Maison P; Balkau B; Souberbielle JC; Cunin P; Vol S; Macquin-Mavier I; Eschwège E;
    Diabet Med; 2007 Sep; 24(9):1012-8. PubMed ID: 17535291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone induced lipolysis during short- and long-term administration in adult Prader-Willi patients.
    Höybye C; Hilding A; Marcus C; Thorén M
    Growth Horm IGF Res; 2005 Dec; 15(6):411-5. PubMed ID: 16230042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of growth hormone on glucose metabolism.
    Møller N; Jørgensen JO; Abildgård N; Orskov L; Schmitz O; Christiansen JS
    Horm Res; 1991; 36 Suppl 1():32-5. PubMed ID: 1806481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone deficiency (GHD) in adult thalassaemic patients.
    Scacchi M; Danesi L; Cattaneo A; Valassi E; Pecori Giraldi F; Argento C; D'Angelo E; Mirra N; Carnelli V; Zanaboni L; Cappellini MD; Cavagnini F
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):790-5. PubMed ID: 17608814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset.
    Columb B; Smethurst LE; Mukherjee A; Jostel A; Shalet SM; Murray RD
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):281-6. PubMed ID: 18702681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.